23-24th September | Amsterdam RAI, Halls 2 & 3
Europe’s leading congress on drug and patient safety, convening C-suite, R&D, and data leaders to shape the future of pharmacovigilance, benefit-risk management, and the role of AI in transforming safety monitoring.
Find us at Booth #200 across both days.
World Patient Safety Congress EU Website
Aman Wasan
CEO – ArisGlobal
Julie Thomas
Vice President, Global Medical Safety – Johnson & Johnson
Connected Intelligence: How Agentic AI Is Transforming Life Sciences Operations
Agentic AI is no longer a future concept. It is already delivering measurable value across pharmacovigilance and R&D operations. This keynote will explore how leading life sciences organizations are using AI-powered agents to streamline workflows, improve productivity, accelerate decision-making, and reduce operational burden across safety, regulatory, quality, and clinical functions. The guests will also discuss why connected data is essential to maximizing AI’s impact, enabling organizations to move beyond siloed processes and create a foundation for more intelligent, efficient, and scalable operations.
Jason Bryant
SVP, Product Management, AI – ArisGlobal
- 23 September 2026 | 12:20pm
- Location: Track 1 Forum – Downstairs
Can You Trust Agentic AI? Governing the Next Era of Pharmacovigilance
As pharmacovigilance moves toward Agentic AI, the conversation is shifting from automation to trust. The challenge is no longer just validating outputs, but governing how AI systems reason, orchestrate workflows, and support decisions within regulated environments. This session explores how organizations can operationalize AI responsibly through transparency, governance, measurable performance, and human oversight. Using real-world examples, we will discuss how concepts such as provenance, inspectability, and behavioural assurance help enable trusted AI in safety operations. Learn how bounded autonomy can accelerate signal detection, case intake, and regulatory decision support while maintaining compliance, accountability, and human control.
Lucinda Smith
Chief Safety Product Officer – ArisGlobal
Panel Discussion
Panelists:
- Andrea Rogers, Executive Director, R&D Informatics, Amgen
- Claudia Schaffer, Head ICSR Management, Merck
- Samuel Wallis, Head of Case Management, Patient Safety, Bristol Myers Squibb
- Claudia Lehmann, VP, Head Global Pharmacovigilance Operations & Systems, Boehringer Ingelheim
- 23 September 2026 | 2:40pm
- Location: Track 1 Forum – Downstairs
From Potential to Trusted Adoption: Scaling Agentic AI in Pharmacovigilance
As AI becomes increasingly embedded across pharmacovigilance, the conversation is shifting from experimentation to trust and operational adoption. In this panel discussion, PV leaders from leading pharmaceutical organizations will share how they are building confidence in AI within regulated environments and what it will take to move beyond 100% manual review of AI-generated outputs. The discussion will explore governance, validation, performance monitoring, and human oversight, as well as the practical challenges of scaling AI while maintaining compliance, quality, and accountability.
Lucinda Smith
Chief Safety Product Officer – ArisGlobal
Param Gill
Associate Vice President – ArisGlobal
Turning Technology into Action: Smarter Signal Management for Better Safety Decisions
Safety data isn’t the problem. Turning it into action is.
Signal management is one of the most critical and most resource-intensive jobs in pharmacovigilance. Safety teams are drowning in fragmented evidence, all while racing to find what actually matters for patients.
This session breaks down three shifts that change the game:
- Knowledge Graphs & Contextual Intelligence – Connect cases, literature, events, and clinical context instantly, so case and context evaluation happens in minutes, not days.
- Agentic Signal Management – Deploy Signals Agents to orchestrate complex workflows, kill the repetitive grind, and evaluate signals faster and smarter.
- Integrated Signal & Risk Management – Unite detection, evaluation, prioritization, and risk management on one platform. One connected path from signal to action.
From data overload to safety intelligence. From detection to action.
Technology built for better, faster, more proactive patient-safety decisions.
